Live Breaking News & Updates on Trans Arterial Micro Perfusion

Stay updated with breaking news from Trans arterial micro perfusion. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

RenovoRx CEO Issues Letter to Shareholders

Recent financing will drive Company towards second interim analysis on pivotal Phase III TIGeR-PaC clinical trial by end of 2024

. ....

Shaunr Bagai , Shaun Bagai , Data Monitoring Committee , Renovorx Inc , Exchange Commission , Company Nasdaq , Securities Exchange , Chief Executive Officer , Fellow Renovorx Shareholders , Trans Arterial Micro Perfusion , Overall Survival , Cancer Research Annual Meeting , Late Breaker Oral Presentation , Medical Oncology World Congress , Gastrointestinal Cancer , New Drug Application , Scientific Advisory Board , Patent Cooperation Treaty , Cell Therapy , Drug Evaluation , Securities Act , Securities Exchange Act , R Pac Phase ,

RenovoRx CEO Issues Letter to Shareholders

RenovoRx, Inc. ("RenovoRx" or the "Company") , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer,. ....

Shaun Bagai , Shaunr Bagai , Securities Exchange , Exchange Commission , Data Monitoring Committee , Company Nasdaq , Renovorx Inc , Chief Executive Officer , Fellow Renovorx Shareholders , Trans Arterial Micro Perfusion , Overall Survival , Cancer Research Annual Meeting , Late Breaker Oral Presentation , Medical Oncology World Congress , Gastrointestinal Cancer , New Drug Application , Scientific Advisory Board , Patent Cooperation Treaty , Cell Therapy , Drug Evaluation , Securities Act , Securities Exchange Act , R Pac Phase ,

RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer

This study will be the Second Clinical Trial Evaluating RenovoGem™, a Combination Drug-Device Product, in a Difficult-to-Access Solid Tumor Cancer

. ....

United States , Hassan Hatoum , Richardl Simmons , Paula Novelli , David Geller , University Of Pittsburgh School Medicine , University Of Pittsburgh Medical Center , Interventional Radiology Research , Exchange Commission , Company Nasdaq , Nasdaq Stock Market , Oklahoma University Ou Health , Liver Cancer Center , Cougar National Principal Investigator , Renovorx Inc , Securities Exchange , Cougar Trial , Leesa Gentry , Senior Vice President , Clinical Operations , Trans Arterial Micro Perfusion , Associate Professor , Pittsburgh Medical , Cancer Center , Pittsburgh School , Principal Investigator ,

Clinical Data Abstract Presentation; IP Portfolio of 9 Patents; Phase 3 Cancer Treatments: RenovoRx NASDAQ: RNXT $RNXT

Clinical Data Abstract Presentation; IP Portfolio of 9 Patents; Phase 3 Cancer Treatments: RenovoRx NASDAQ: RNXT $RNXT
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.

United States , Salt Lake City , France General , Michaelj Pishvaian , Shaun Bagai , Gustave Roussy , Frontpagestocks Corporateads , Shripal Gandhi , Michel Ducreux , Research Supports Renovorx Lead Oncology Product , Renovorx Inc , Imugene Ltd , Miami Cancer Institute , University Of Paris Sud , Data Monitoring Committee , Gastrointestinal Tract Cancer Group , European Organisation For Research , Research Supports Lead Oncology Product , Company Scientific Advisory Board , Vascular Institute , Society Of Interventional Radiology Annual Scientific Meeting , Saclay University , School Of Medicine , Society Of Interventional Radiology , Clinical Data Abstract Presentation , New Application Bolstering ,